Alpha 2.0
Login Register
» Articles » PMID: 32915710

Case of Fatal Immune-Related Skin Toxicity From Sequential Use of Osimertinib After Pembrolizumab: Lessons for Drug Sequencing in Never-Smoking Non-Small-Cell Lung Cancer

Overview
Journal JCO Oncol Pract
Specialty Oncology
Date 2020 Sep 11
PMID 32915710
Citations 8
Authors
Wanyuan Cui
Chantal Cotter
Katherina Bernadette Sreter
Kara Heelan
Daniel Creamer
Tanya N Basu
Jonathan Handy
Sarah Walsh
Sanjay Popat
Affiliations
Soon will be listed here.
Citing Articles

Stevens-Johnson syndrome and toxic epidermal necrolysis associated with immune checkpoint inhibitors: a systematic review.

Zhou J, Wang C, Li J, Zhang H, He C Front Immunol. 2024; 15:1414136.

PMID: 39072330 PMC: 11272453. DOI: 10.3389/fimmu.2024.1414136.

Immunological Drug-Drug Interactions Affect the Efficacy and Safety of Immune Checkpoint Inhibitor Therapies.

Grice S, Olsson-Brown A, Naisbitt D, Hammond S Chem Res Toxicol. 2024; 37(7):1086-1103.

PMID: 38912648 PMC: 11256900. DOI: 10.1021/acs.chemrestox.4c00067.

Is Immunotherapy Beneficial in Patients with Oncogene-Addicted Non-Small Cell Lung Cancers? A Narrative Review.

McMahon D, McLaughlin R, Naidoo J Cancers (Basel). 2024; 16(3).

PMID: 38339280 PMC: 10854575. DOI: 10.3390/cancers16030527.

Osimertinib tolerance in a patient with Stevens Johnson syndrome during osimertinib therapy after treatment with pembrolizumab.

Lopez M, Hagopian G, Doan L, Lee B, Rojek N, Smith J Allergy Asthma Clin Immunol. 2023; 19(1):93.

PMID: 37898814 PMC: 10612162. DOI: 10.1186/s13223-023-00849-5.

Does immune checkpoint inhibitor therapy increase the frequency of adverse reactions to concomitant medications?.

Hammond S, Olsson-Brown A, Grice S, Naisbitt D Clin Exp Allergy. 2022; 52(5):600-603.

PMID: 35338535 PMC: 9311166. DOI: 10.1111/cea.14134.